FoxHollow Stock Up 25% In Q3 On SilverHawk Profitability, Merck Deal
This article was originally published in The Gray Sheet
Executive Summary
FoxHollow's stock advanced 25.1% in the third quarter as investors took notice of the firm's first profitable quarter, increased adoption of the company's SilverHawk peripheral vessel plaque excision system and an expanded research agreement with Merck